Document 0331
 DOCN  M9590331
 TI    Sexual transmission of zidovudine resistant HIV-1. Sydney Primary HIV
       Infection Study Group.
 DT    9509
 AU    Imrie A; Carr A; Duncombe C; Vizzard J; Zheng N; Finlayson R; Hurren L;
       Roggensack M; Kaldor J; Penny R; et al; Centre for Immunology, St
       Vincent's Hospital, Sydney, Australia.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:168 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291768
 AB    HIV-1 with decreased in-vitro susceptibility to zidovudine (ZDV) may be
       isolated from patients on prolonged therapy. We examined the frequency
       with which ZDV resistant variants of HIV-1 were isolated from 27
       homosexual men with primary HIV-1 infection (PHI), as well as from 5
       sexual partners. ZDV susceptibility was assessed using donor PBMC;
       selected isolates were analyzed for mutations at codon 215 of the viral
       RT by selective PCR. Isolates from 5 virus source patients were analyzed
       for ZDV resistance phenotype and genotype HIV-1 with a resistant
       phenotype and genotype was isolated from one man 19 days after onset of
       his primary infection illness as well as from his sexual partner, who
       had commenced ZDV treatment 25 months prior to transmission. Despite ZDV
       therapy for treatment of PHI, HIV-1 wild-type at codon 215 had replaced
       the resistant variants within 3 months of transmission. This rate of
       transmission (1/27, 3.7%) is not significantly different at the 0.05
       level from the proportion of people living with HIV-1 infection in
       Australia who were estimated to have developed zidovudine resistance. 12
       months after seroconversion this patient is clinically well, with
       category A1 HIV disease. The long term clinical consequences of primary
       infection with drug resistant variants of HIV-1 remain to be determined.
 DE    Drug Resistance, Microbial/GENETICS  Follow-Up Studies  Homosexuality,
       Male  Human  HIV Infections/DRUG THERAPY/*TRANSMISSION/VIROLOGY
       HIV-1/*DRUG EFFECTS/GENETICS  Male  Phenotype  *Sex Behavior  Sexual
       Partners  Zidovudine/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).